Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Instil Bio, Inc.

Get SEC filing alerts via email and in your feed for Instil Bio, Inc.

TIL

Instil Bio, Inc.

About Instil Bio, Inc.

Instil Bio, Inc. is a biopharmaceutical company focused on developing novel immunotherapies for cancer. Its pipeline includes bispecific antibodies targeting PD-L1 and VEGF, as well as other immune-modulating agents. The company collaborates globally, advancing clinical trials for solid tumor treatments, and aims to commercialize approved therapies. Its core strengths lie in innovative biologic platforms, strategic licensing, and a focus on unmet medical needs in oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Instil Bio, Inc.

1
1
Instil Bio, Inc. Instil Bio Reports $4.2 Million Net Loss in Q1 2026, Significant Expense Reductions Noted

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Instil Bio, Inc. Instil Bio Reports $71.4 Million Net Loss for Fiscal Year 2025, Discontinues Lead Product Candidate

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Instil Bio, Inc. Instil Bio Reports Q3 2025 Financial Results with Improved Net Loss of $13.6 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Instil Bio, Inc. Instil Bio Reports $21.4 Million Net Loss for Q2 2025, Increased Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Instil Bio, Inc. Instil Bio Reports $28.2 Million Net Loss in Q1 2025, Driven by Increased Restructuring Charges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Instil Bio, Inc. Instil Bio Reports $74.1 Million Net Loss for 2024, Highlights Key Developments in Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Instil Bio, Inc. Instil Bio Reports Improved Financials, Reduced Operating Expenses, and Strategic Developments in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments